logo
Book a meeting
Ichosia Biotechnology

Ichosia Biotechnology

Biotechnology, 17 Briden St, Worcester, Massachusetts, 01605, United States, 1-10 Employees

ichosia.com

  • facebook
  • twitter
  • LinkedIn

Who is ICHOSIA BIOTECHNOLOGY

Ichosia Biotechnology is developing a scalable method of mass-producing an enhanced red blood product, Erythrosyn, by leveraging proprietary genetic engineering techniques. Erythrosyn is ...

Read More

lock icon Get Full Access
map
  • 17 Briden St, Worcester, Massachusetts, 01605, United States Headquarters: 17 Briden St, Worcester, Massachusetts, 01605, United States
  • 2019 Date Founded: 2019
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from ICHOSIA BIOTECHNOLOGY

Ichosia Biotechnology Org Chart and Mapping

Employees
Carter Pew

Carter Pew

Chief of Staff, Vice President of Business Development

See Full Org Chart arrow
email-formate-icon
View Email Formats for Ichosia Biotechnology
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Ichosia Biotechnology

Answer: Ichosia Biotechnology's headquarters are located at 17 Briden St, Worcester, Massachusetts, 01605, United States

Answer: Ichosia Biotechnology's official website is https://ichosia.com

Answer: Ichosia Biotechnology's revenue is Under $1 Million

Answer: Ichosia Biotechnology's SIC: 7389

Answer: Ichosia Biotechnology has 1-10 employees

Answer: Ichosia Biotechnology is in Biotechnology

Answer: Ichosia Biotechnology contact info: Phone number: Website: https://ichosia.com

Answer: Ichosia Biotechnology is developing a scalable method of mass-producing an enhanced red blood product, Erythrosyn, by leveraging proprietary genetic engineering techniques. Erythrosyn is created by genetically engineering human stem cells to transform into fully functioning red blood cell. By transitioning this natural erythropoietin process from the body into the laboratory, Erythrosyn is being designed to be producible on demand, universally compatible and more cost effective than donor blood.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access